Phase 1 dose-escalation, safety / tolerability and preliminary efficacy study of intratumoral and subcutaneous administration of GEN0101 in patients with recurrence of castration resistant prostate cancer
Phase of Trial: Phase I
Latest Information Update: 21 Oct 2017
At a glance
- Drugs GEN 0101 (Primary) ; GEN 0101 (Primary)
- Indications Prostate cancer
- Focus Adverse reactions
- Sponsors Ishihara Sangyo Kaisha
- 18 Oct 2017 Status changed from recruiting to completed.
- 10 Jun 2017 Biomarkers information updated
- 15 Jun 2015 Status changed from not yet recruiting to recruiting as reported by University Hospital Medical Information Network - Japan record.